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Models describing the structural changes mediating Cys loop
receptor activation generally give little attention to the possibil-
ity that different agonists may promote activation via distinct
M2 pore-lining domain structural rearrangements. We investi-
gated this question by comparing the effects of different ligands
on the conformation of the external portion of the homomeric
1 glycine receptor M2 domain. Conformational flexibility was
assessed by tethering a rhodamine fluorophore to cysteines
introduced at the 19 or 22 positions and monitoring fluores-
cence and current changes during channel activation. During
glycine activation, fluorescence of the label attached to R19C
increased by 20%, and the emission peak shifted to lower
wavelengths, consistent with a more hydrophobic fluorophore
environment. In contrast, ivermectin activated the receptors with-
out producing a fluorescence change. Although taurine and-ala-
nine were weak partial agonists at the 1R19C glycine receptor,
they induced large fluorescence changes. Propofol, which drasti-
cally enhanced these currents, did not induce a glycine-like blue
shift in the spectral emission peak. The inhibitors strychnine and
picrotoxin elicited fluorescence and current changes as expected
for a competitive antagonist and an open channel blocker, respec-
tively.Glycineandtaurine (or-alanine)alsoproducedan increase
and a decrease, respectively, in the fluorescence of a label attached
to the nearby L22C residue. Thus, results from two separate
labeled residues support the conclusion that the glycine receptor
M2domain respondswithdistinct conformational changes toacti-
vation by different agonists.
Glycine receptor (GlyR)4 chloride channels mediate inhibi-
tory neurotransmission in the central nervous system (1). They
comprise an assembly of five subunits that are each composed
of a large N-terminal extracellular ligand-binding domain and
four transmembrane -helices (M1–M4). Cryo-electron
microscopy images of the homologous Torpedo electropax nic-
otinic acetylcholine receptor (nAChR) transmembrane region
reveals that the pore-lining M2 domains are kinked radially
inward to form a central constriction at the membrane mid-
point (2). There is currently a great deal of interest in under-
standing howM2domainsmove to open the channel. Although
the original model proposed a drastic rotation of M2 domains
about their long axes (3), more recent evidence suggests that
there is little if any rotation during receptor activation (4–6).
The precise nature of the structural change remains a matter
for debate.
The central pore kink is likely to introduce a degree of struc-
tural discontinuity because the hydrogen bonds responsible for
maintaining -helix rigidity are most likely broken. The kink
may therefore act as a swivel enabling the outer half of M2
to move asynchronously with the inner half, where the gate is
most likely positioned. Indeed, several lines of evidence suggest
gating is mediated by a backbone rearrangement at this mid-
point (7–10). In addition, a rate equilibrium free energy state
analysis shows that the M2–M3 domain is positioned midway
along the agonist-induced “conformational wave” that extends
from the ligand binding domain to the gate (11). These consid-
erations imply that the outer part ofM2 should be an informative
place to investigate the structural basis of receptor activation, as
themovements in this regionshouldnot reflect either thoseoccur-
ring at the ligand binding site or the activation gate. Thus, in this
study we probe conformational changes at the 19 and 22 resi-
dues, near the external end ofM2.
Currentmodels of Cys loop receptor activation consider only
structural changes associated with transitions from the resting
closed state to the agonist-induced open state (5, 6, 12, 13).
Relatively little attention has been given to the possibility that
different agonists and pharmacological modulators may pro-
mote different structural conformations in the pore region.
However, it has been suggested on the basis of substituted cys-
teine accessibility studies that the pore blocker, picrotoxin, can
change the conformation of the outer GlyR pore region sug-
gesting in turn that it may interact allosterically with agonist-
induced conformational changes (14). Our aim is to investigate
the conformational changes induced by agonists, antagonists,
and allosteric modulators by covalently labeling different resi-
dues near the extracellular M2 boundary with the sulfhydryl-
reactive fluorophores, methanethiosulfonate-rhodamine
(MTSR) and tetramethylrhodamine-maleimide (TMRM), and
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simultaneously measuring current changes and fluorescence
changes (15, 16). This approach has been employed so far in
only a few studies on Cys loop receptors (15, 17, 18). A partic-
ular advantage of the GlyR is that it displays little or no desen-
sitization thereby facilitating the quantitation of ligand-in-
duced fluorescence spectral shifts.
EXPERIMENTAL PROCEDURES
Chemicals—Glycine, CaCl2, MgCl2, KCl, NaCl, and glycerol
were all purchased from Ajax Finechem (Seven Hills, New
South Wales, Australia). HEPES was purchased from Amresco
(Solon, OH). Sulforhodamine methanethiosulfonate (MTSR,
Toronto Research Chemicals, North York, Ontario, Canada)
and tetramethylrhodamine-5-maleimide (TMRM, Invitrogen)
were dissolved in dimethyl sulfoxide (Me2SO) and stored at
20 °C. Picrotoxin (Sigma), ginkgolide C (Tauto Biotech Co.,
Shanghai, China), and ivermectin (Sigma) were dissolved in
Me2SO and stored at20 °C. Propofol (2,6-diisopropylphenol)
was purchased from Sigma and stored at 4 °C. Strychnine
(Sigma) was dissolved in water and stored at 20 °C. Taurine
(Sigma) and -alanine (Sigma) were
also dissolved in water and stored at
4 °C.
Molecular Biology—The human
GlyR 1 subunit cDNA was sub-
cloned into the pGEMHE vector.
All constructs used in this study
contained the functionally silent
C41A mutation, which eliminated
the sole uncross-linked extracellu-
lar sulfhydryl group (19). Site-di-
rected mutagenesis to generate
the R19C, S21C, and L22C
mutants was performed with the
QuickChange mutagenesis kit
(Stratagene, La Jolla, CA). Success-
ful incorporation of the mutations
was confirmed through automated
sequencing of the entire cDNA
coding region. The mMessage
mMachine kit (Ambion, Austin,
TX) was used to generate capped
mRNA for oocyte injection. mRNA
concentrationswere adjusted to 200
pg/nl and aliquots stored at70 °C.
Oocyte Preparation, Injection,
and Labeling—FemaleXenopus lae-
vis (Xenopus Express, France) frogs
were anesthetized, and stage VI
oocytes were removed from ovaries
andwashed thoroughly inOR-2 (2.5
mMNaCl, 2 mMKCl, 1mMMgCl2, 5
mM HEPES, pH 7.4). The oocytes
were incubated in collagenase
(Sigma) in OR-2 for 2 h at room
temperature, rinsed, and stored at
18 °C.
All oocytes were injected with 10
ng of mRNA into the cytosol. To achieve the high levels of
expression required for the detection of the fluorescent signal
over the background (because of oocyte autofluorescence and
nonspecific binding of the dye), the oocytes were incubated for
3–10 days after injection at 18 °C. The incubation solution con-
tained 96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5
mM HEPES, 0.6 mM theophylline, 2.5 mM pyruvic acid, 50
g/ml gentamycin (Cambrex Corp., East Rutherford, NJ), 5%
horse serum (Hyclone, Logan, UT), pH 7.4.
To maximize surface expression of receptors prior to label-
ing, oocytes were incubated at room temperature for 2 h. The
oocytes were then transferred into ND96 (96 mM NaCl, 2 mM
KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES, pH 7.4) and
stored on ice. For labeling, oocytes were transferred into the
labeling solution containing 10 M MTSR in ND96 for 25 s or
10 M TMRM in ND96 for 60 min. The oocytes were then
washed and stored in ND96 for up to 6 h before recording. All
labeling steps were performed on ice.
Voltage Clamp Fluorometry (VCF)—For VCF experiments,
an inverted Nikon Eclipse TE300 microscope (Nikon Instru-
FIGURE 1. Effects ofMTSR labeling on1WT and1R19CGlyRs. A, glycine-evoked currents recorded from
oocytes injected with 1WT (upper panel) and 1R19C (lower panel) after labeling with MTSR. B, glycine-
evoked currents recorded from oocytes injected with 1WT (upper panel) or 1R19C (lower panel) before (left
panel) and after (right panel) labeling with MTSR. C, glycine dose-response relations for 1WT and 1R19C
before and after labeling with MTSR. Black horizontal bars indicate duration of glycine application. All concen-
trations are inmM.D, ribbonmodel of threepore-facingnAChRM2helices and theirM2–M3 linkers inblack and
gray (based on Protein Data Bank code 2BG9). A space filling model of the 9 leucine is shown in dark blue. A
space filling model of MTSR molecule is tethered to the 19 position (approximate orientation based on H. A.
Lester andM. I. Dibas, manuscript in preparation). Color code is as follows:white, hydrogen; light blue, carbon;
red, oxygen; dark blue, nitrogen; and yellow, sulfur.
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ments, Kawasaki, Japan) was equipped with a high-Q TRITC
filter set (Chroma Technology, Rockingham, VT), a Plan Fluor
40 objective lens (N.A. 0.6, WD 3.7–2.7 mm) (Nikon Instru-
ments, Kawasaki, Japan), and a PhotoMax 200 photodiode
detection system (Dagan Corp., Minneapolis, MN) attached to
the side port of the microscope. An excitation filter wheel
including a shutter and an emission filter wheel were controlled
through a Lambda 10-2 unit (Sutter Instruments, Novato, CA).
A Lambda LS 175-watt xenon arc lamp served as a light source
and was coupled to the microscope
via a liquid light guide (Sutter
Instruments, Novato, CA). The
design of the custom-made record-
ing chamber is described in Ref. 15.
An automated perfusion system
operated by a Valvebank 8 module
(AutoMate Scientific, San Fran-
cisco, CA) was used for perfusion of
the recording chamber.
Electrodes for two-electrode volt-
age clamp recordings were filled
with 3 M CsCl and moved by auto-
mated ROE-200 micromanipula-
tors coupled to an MPC-200
controller (Sutter Instruments,
Novarto, CA). Cells were voltage-
clamped at a holding potential of
40 mV in all experiments, and
currents were recorded using a
Gene Clamp 500B amplifier
(Molecular Devices). Current and
fluorescence traceswere acquired at
200 Hz via a Digidata 1322A inter-
face and Clampex 9.2 software
(Molecular Devices). The fluores-
cence signal was further digitally fil-
tered at 1–2 Hz with an eight-pole
Bessel filter for analysis and display.
The base line was corrected for
bleaching where appropriate. All
values for changes in fluorescence
indicate an increase in fluorescence,
unless stated otherwise. The empir-
ical Hill equation, fitted with a
nonlinear least squares algorithm
(SigmaPlot 9.0, Systat Software, Point Richmond, CA), was
used to obtain half-maximal concentrations (EC50 or IC50) and
Hill coefficient (nH) values for ligand-induced activation and
inhibition. All results are expressed asmeans S.E. of themean
of five or more independent experiments.
Spectral Analysis—For spectral analysis a MicroSpec 2150i
(Acton Research Corp., Acton, MA) coupled to an ORCA-ER
CCD camera (Hamamatsu, Hamamatsu City, Japan) replaced
the photodiode detection system on the side port of the micro-
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FIGURE 2. Close coupling of current and fluorescence changes and spectral analysis of MTSR-labeled
1R19C oocytes. A, glycine-evoked current (upper panel) and fluorescence (lower panel) recordings from
MTSR-labeled 1R19C oocytes. B, glycine dose-response relation for current and fluorescence in MTSR-la-
beled1R19C oocytes. C, spectral emission fromMTSR-labeled1R19C oocytes before, after, and during the
application of 1 and 30 mM glycine (average of five cells each). D, difference emission spectra from MTSR-
labeled1WTand1R19Coocytes recordedduring applicationof glycine. Spectra recorded in the absenceof
glycine were subtracted from spectra recorded in the presence of glycine (average of five cells). Red and blue
traces were recorded in the presence of 20 and 1 mM glycine concentrations, respectively. The black trace
shows the difference emission spectrum obtained from aWT-injected oocyte after application of a saturating
glycine concentration.Redandblue tracesare shownnormalized in the inset, alongwith the spectrumrecorded
in the absence of glycine (gray trace, normalized to the trace obtained with 1 mM glycine).
TABLE 1
Summary of results for glycine-evoked current and fluorescence recordings
Displayed are the values for half-maximal activation (EC50), Hill coefficient (nH), number of experiments (n), and maximal current and fluorescence responses (Imax and
Fmax, respectively). NA indicates not applicable. All results for fluorescence are shown in boldface.
Construct EC50 nH n Imax Fmax n
M A %
WT unlabeled 21.5 0.1 2.9 0.1 5 10.0 0.6 NA 9
WT labeled 19.1 0.1 3.0 0.1 6 8.7 0.6 NA 6
S21C unlabeled 21.1 0.1 1.9 0.1 5 6.8 0.3 NA 5
S21C labeled 24.3 0.6 1.9 0.1 3 6.2 0.4 NA 3
S22C unlabeled 781.0 7.2 1.2 0.1 7 7.3 0.8 NA 7
S22C labeled 215.7 0.2 1.9 0.1 6 7.7 0.4 NA 6
R19C unlabeled 4450 190 1.7 0.1 7 9.3 1.6 NA 5
R19C labeled 994 14 1.7 0.1 7 8.3 0.6 NA 19
R19C F 1074 46 1.5 0.1 7 NA 21.4 1.9 19
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scope. The spectrometerwas operated using SpectraPromono-
chromator software (Acton Research Corp., Acton, MA). For
excitation, a HQ535/50 filter was used in combination with a
Q565LP dichroic mirror (Chroma Technology, Rockingham,
VT); no emission filter was used. Prior to the experiment, the
spectrometer was calibrated using the 434, 546, and 577 nm
lines of a mercury lamp spectrum.
To analyze spectra, the image of the region of interest to be
monitored was aligned with the slit of the spectrometer. Fluo-
rescence from the region of interest
was reflected onto the grating (300
g/mm; 500 nm blaze), and the
extracted spectrum was imaged on
the ORCA-ER CCD (chip size
1344  1024 pixels) using Meta-
Morph 6.2 (Universal Imaging
Corp., Downington, PA). The x
axis of the resulting “spectral
image” represents the wavelength
dimension, whereas the y axis rep-
resents the one-dimensional spa-
tial dimension of the slit. The
wavelength coverage for this com-
bination of grating and camera
was 170 nm. Adjacent averaging
(15 points) was used to smooth
recorded spectra (ORIGIN 6.0,
Microcal Software Inc., North-
ampton, MA).
RESULTS
Specific MTSR Labeling of the
1R19C GlyR—Fig. 1A shows
examples of glycine-evoked cur-
rents recorded from oocytes
injected with 1WT RNA (upper
panel) or mutant 1R19C RNA
(lower panel). The averaged glycine
dose-response curves are shown in
Fig. 1C. In this and all subsequent
figures displaying dose-response
curves, the continuous lines repre-
sent fits of the Hill equation to the
averaged points. Table 1 shows
themean EC50 and nH values, deter-
mined by averaging the parameters
determined from curve fits to indi-
vidual dose responses. Table 1 also
shows the mean Imax values. As
reported previously (20), the
1R19C mutation results in a dra-
matically decreased glycine sensi-
tivity. Themean Imax was not signif-
icantly different in 1R19C relative
to 1WT receptors (9.3  1.6 A,
n 5, versus 10.0 0.6 A, n 9).
The effect of MTSR labeling on gly-
cine-evoked currents was also stud-
ied. As shown in the example in Fig.
1B (upper panel), our standard MTSR labeling protocol pro-
duced no significant change (11.7 8.1%, n 8) in the mag-
nitude of currents activated by EC10 (5 M) glycine in 1WT
GlyRs (Fig. 1B, upper panel). However, EC10 (1 mM) glycine
currents were strongly potentiated in1R19CGlyRs following
MTSR labeling with amean current increase of 471 68% (n
6) (e.g. Fig. 1B, lower panel). As shown in Fig. 1C, this was caused
by a leftward shift in the 1R19C GlyR glycine EC50 value,
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FIGURE 3. Effects of ivermectin, taurine, and -alanine on current and fluorescence fromMTSR-labeled
1R19C oocytes. A, current (upper panel) and fluorescence (lower panel) traces of MTSR-labeled 1R19C
oocyte during glycine (gly) and ivermectin (ivm) application. The fluorescence recording was interrupted to
minimize photobleaching. B, current (upper panel) and fluorescence (lower panel) traces of MTSR-labeled
1R19C oocyte during glycine, ivermectin, and simultaneous ivermectin and strychnine (str) application.
C and D, current (upper panel) and fluorescence (lower panel) traces of MTSR-labeled 1R19C oocytes during
consecutive saturating glycine (gly) and taurine (tau) (A) or glycine and -alanine (-ala) (D) applications.
Horizontal bars indicate duration of applications. E, current and fluorescence dose-response relations for gly-
cine, taurine, and -alanine in MTSR-labeled 1R19C oocytes. F, difference emission spectra from MTSR-
labeled1R19Coocytes recordedduring application of saturating [glycine] and [taurine].Red andblack traces
are shown normalized in the inset, along with the spectrum recorded in the absence of glycine (gray trace,
normalized to the trace obtainedwith 1mM glycine).G,difference emission spectra fromMTSR-labeled1R19C
oocytes recordedduringapplicationof saturating [glycine] and [-alanine].Redandblack tracesare shownnormal-
ized in the inset, along with the spectrum recorded in the absence of glycine (gray trace, normalized to the trace
obtainedwith 1mMglycine). Difference emission spectrawere calculated as described in Fig. 2D.
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although the nH remained unchanged (Table 1). As expected, the
mean glycine EC50 of the 1WT GlyR was not significantly
changed by the MTSR labeling procedure (Fig. 1C and Table 1).
Fig. 1D shows amodel of three nAChRM2 helices (based on Pro-
tein Data Bank code 2BG9), one of which shows the approximate
relative locations of the labeled rhodamine5 and the 9 leucine
residue thought to be part of the channel gate.
Glycine-evoked Changes in Fluorescence Intensity at R19C—
MTSR treatment of oocytes injected with 1R19C mRNA
resulted inan3.5-fold increase in resting fluorescencecompared
with that observed in identically treated uninjected oocytes or
oocytes injectedwith1WTmRNA(datanot shown).VCFexper-
iments showed that glycine application produced changes in fluo-
rescence intensity (F) in 1R19C-injected oocytes that were
coincident in time with the activated chloride current (I) (Fig.
2A), with relative changes in fluorescence (F/F) regularly reach-
ing 20% at saturating glycine concentrations. In contrast, no sig-
nificantFwas ever observedwith uninjected or1WT-injected
oocytes. When normalized, the I and F glycine dose
responses were virtually superimposed (Fig. 2B and Table 1),
strongly suggesting a tight coupling between conformational
changes at the 19 residue and at the
channel gate during glycine-in-
duced activation.
Spectral analysis of the fluores-
cence signal from MTSR-labeled
1R19C GlyRs revealed that the
fluorescence increasewas accompa-
nied by an10 nmblue shift (n 6)
in the MTSR emission peak during
full receptor activation (Fig. 2,C and
D). The magnitude of this shift was
concentration-dependent, with
EC50 (1 mM) glycine producing
roughly half of the shift produced
by a saturating (20 mM) glycine
concentration (Fig. 2, C and D).
The blue shift in the MTSR emis-
sion peak is characteristic of an
increase in hydrophobicity in the
fluorophore environment, most
likely reflecting a movement of the
fluorophore to a more hydropho-
bic environment in the open state
(15). As expected, MTSR-incu-
bated oocytes expressing 1WT
GlyRs did not show F or spectral
shifts (Fig. 2D).
Effects of Other Agonists on R19C
Fluorescence Changes—The anti-
helminthic compound, ivermectin,
binds to an as yet unidentified bind-
ing site and activates the GlyR in an
irreversible manner (21). To con-
firm the previous conclusion that it
activates the GlyR via a different
mechanism from glycine (21), we sought to compare the rela-
tionship between I and F produced by ivermectin with that
produced by glycine. In MTSR-labeled 1R19C GlyRs, 10 M
ivermectin evoked slowly developing currents that were
roughly double the size of those produced by 1 mM glycine
(203  30%, n  10). Despite this large current, no significant
increase in the fluorescence intensity was ever observed (e.g.
Fig. 3A). Indeed, themean fluorescence change in eight oocytes
showing robust glycine currents, the F response was only
0.5 0.1%. As observed previously (21), the currents evoked by
10M ivermectinwere onlyweakly sensitive to strychnine, with
10 M strychnine reducing current magnitude by 18.9  0.7%
(n 4, Fig. 3B). No ivermectin-gated currents were observed in
uninjected oocytes (n  3). Taken together, these results con-
firm that ivermectin activates GlyRs by a mechanism different
from glycine.
Taurine and -alanine are low efficacy agonists of 1WT
GlyRs, with taurine having a lower efficacy than -alanine (22).
Both compounds are converted into antagonists by a variety of
R19 mutations, including R19C (20, 23, 24). These actions
suggest that taurine and -alanine bind to the 1R19C GlyR
without activating the receptor and thereby they act as classical
competitive antagonists of glycine binding. If this hypothesis is5 H. A. Lester and M. I. Dibas, manuscript in preparation.
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FIGURE 4. The TMRM-labeled 1L22C mutant GlyR differentiates between activation by glycine and
taurine or-alanine. A, examples of simultaneously recorded glycine-evoked current (upper panel) and fluo-
rescence changes (lower panel) from MTSR-labeled 1L22C GlyRs (left), from TMRM-labeled 1L22C GlyRs
(center), and fromMTSR-labeled1R19CGlyRs (right).Horizontal bars indicate duration of applications. Differ-
ent fluorophores give different responses when attached to the same residue. B, glycine dose-response rela-
tions for currents in unlabeled and TMRM-labeled 1L22C-expressing oocytes. TMRM labeling causes a sig-
nificant leftward shift in glycine sensitivity. C and D, simultaneously recorded current (upper panel) and
fluorescence (lower panel) recordings fromTMRM-labeled1L22Coocytes following the application of 10mM
taurine and 3 mM glycine (C) or 10 mM -alanine and 3 mM glycine (D). Dashed lines indicate periods of inter-
rupted illumination to prevent photobleaching between applications.
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correct, their binding should not produce significant F. We
sought to investigate whether these ligands produced a signifi-
cant F change upon receptor binding and, if so, whether this
was spectrally similar to that produced by glycine. As expected,
a 50 mM concentration of taurine did not produce a significant
I, although small, nA-sized currents were regularly recorded.
Nevertheless, 50 mM taurine pro-
duced large changes in F, with a
mean value near 35% that evoked by
a saturating glycine concentration
(Fig. 3C). BothI andF stimulated
by taurine were completely blocked
by 10 M strychnine (data not
shown). Similar results were
obtained with -alanine. A 50 mM
concentration of -alanine evoked
only a very small current (4% that
produced by saturating glycine in
the same oocyte), but it evoked a
large F that was roughly 60% that
produced by a saturating glycine
concentration (Fig. 3D). Again, both
I and F stimulated by -alanine
were potently blocked by 10 M
strychnine (data not shown).
The taurine-activated current
was too small to be fitted with con-
fidence to the Hill equation (n 
8). However, Hill equation fits to
taurineF dose responses (Fig. 3E)
from the same eight oocytes
yielded a mean EC50 of 2.4  0.4
mM and nH of 0.9  0.1. Applica-
tions of increasing -alanine con-
centrations revealed a close rela-
tionship between F and I with
no significant differences in their
EC50 and nH values (Fig. 3E). The
F dose response was fitted with a
mean EC50 of 2.02  0.34 mM and
an nH of 0.8  0.1, whereas the I
dose response was fitted with an
EC50 of 2.61  0.93 mM and an nH
of 1.1  0.4 (n  6 for each). To
facilitate comparison with glycine-
mediated responses, Fig. 3E also
shows the I and F dose response
relationships for glycine activa-
tion. The fluorescence and current
maxima for taurine and -alanine
were both normalized to those
produced by glycine in the same
oocyte.
Given that the relationship
betweenI andF produced by gly-
cine activation was not preserved
during receptor activation by tau-
rine or -alanine, we hypothesized
that these compounds produced different conformational
changes at the 19 residue. We investigated this by measuring
the spectral changes produced by both compounds. As
shown in Fig. 3F, taurine binding produced no detectable
spectral shift, whereas the spectral shift produced by -ala-
nine (5 nm) was much smaller than that produced by gly-
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cine (Fig. 3G). Together these results strongly suggest that
the binding of these weak partial agonists results in different
conformational changes from those produced by glycine.
Fluorescence Responses of Other Labeled Residues in the
Extracellular M2 Region—As the R19C mutation impacts
severely on receptor function, we assessed whether other cys-
teinemutants in the extracellularM2 regionwith less impact on
receptor function show a similar pattern of differential
responses to different agonists. A previous study (20) showed
that cysteine substitutions at the 21 and 22 positions disrupt
receptor function to a lesser degree than the R19C mutation.
Thus, we focused on these two residues. When injected into
oocytes, the 1S21C GlyR exhibited a WT-like glycine EC50,
although the nH was significantly reduced (Table 1). The
1S21C-injected oocytes showed no evidence of labeling by
either MTSR or TMRM. Incubation with MTSR or TMRM in
the presence or absence of 100 M glycine produced no signif-
icant F in response to saturating (3 mM) glycine applications
(n  3 each; data not shown), and fluorophore labeling pro-
duced no change in1S21CGlyR electrophysiological proper-
ties (Table 1). We conclude that 1S21C is either not labeled
by these fluorophores or that it experiences no change inmicro-
environment during receptor activation.
The 1L22C GlyR showed robust expression with electro-
physiological properties intermediate between those of 1WT
and 1R19C (Table 1). Importantly, taurine and -alanine
acted as strong partial agonists (see below), as at 1WT recep-
tors.When receptors were labeledwithMTSR, no change inF
could be detected, even at saturating (3mM) glycine concentra-
tions (n 4) (Fig. 4A). However, following labeling by TMRM,
1L22C-injected oocytes showed a small but significant F
(1.5  0.3%, n  13) at saturating glycine concentrations (Fig.
4A). TMRM labeling also produced a significant increase in the
glycine sensitivity of 1L22C GlyRs (Table 1 and Fig. 4B). The
small size of these signals precluded quantitation or spectral
analysis of the F response. In contrast to the effect of glycine,
application of saturating (10 mM) concentrations of taurine or
-alanine evoked a significant decrease in F (Fig. 4, C and D).
Taurine induced amaximal current of 1.7 0.4A and aF of
1.1 0.2% (n 8). -Alanine induced a maximal current of
3.1 0.3 A and a F of1.1 0.3% (n 7). We then tested
whether the sign of the fluorescence change simply depended
on the size of the current or was indeed agonist-specific. Appli-
cation of a low (100M) glycine concentration evoked currents
of 1.6 0.3 A (n 7), a value not significantly different from
those evoked by 10 mM taurine (1.7  0.4 A). However, this
concentration of glycine produced no significant F (0.0 
0.1% compared with1.1 0.2%) (n 7). A similar result was
obtained for -alanine, where currents induced by 300 M gly-
cine were not significantly different from those evoked by 10
mM-alanine (3.8 0.6Aand 3.1 0.3A, respectively), but
the respective fluorescence changes were significantly different
in size and sign (0.3 0.2% compared with1.1 0.3%; both
n  7). Together these results demonstrate that glycine pro-
duces a different conformational change at L22C relative to
those produced by taurine and -alanine.
Effects of GlyR Inhibitors on R19C Fluorescence Changes—
We next sought to compare the effects on the relationship
between I and F of a putative classical competitive antago-
nist, strychnine, an allosteric inhibitor, picrotoxin, and a puta-
tive classical channel blocker, ginkgolide C. The molecular
pharmacology of each of these compounds at theGlyR has been
reviewed recently (25). When applied alone, strychnine did not
evoke significant I or F changes, even at a concentration of
10 M (Fig. 5A). However, when co-applied with 1 mM glycine,
10 M strychnine simultaneously decreased I and F values
(Fig. 5B). As shown in Fig. 5C, the sensitivities of I and F to
strychnine were very similar. Analysis of the strychnine I
dose-response relationships yielded IC50 and nH values of
114.2  9.4 nM and 1.4  0.1 (n  5), whereas the F dose
responses were fitted by IC50 and nH values of 142.5 14.4 nM
and 1.3  0.2 (n  5). Thus, strychnine itself cannot induce
conformational changes that are detectable with a fluorophore
attached to 1R19C, although it can antagonize glycine-in-
duced conformational changes. This response profile is
expected for a classical competitive antagonist.
On the basis of a substituted cysteine accessibility analysis, it
was recently proposed that picrotoxin can induce a conforma-
tional change in the M2–M3 loop that is not produced by gly-
cine (14).We thus hypothesized that picrotoxin may produce a
different relationship betweenI andF than was produced by
glycine. Application of picrotoxin alone did not produce any
changes inI orF, even at a concentration of 50M (Fig. 5D).
Although co-application of 50Mpicrotoxin with 1mM glycine
potently blocked the current, the F remained intact (Fig. 5E).
Dose-response analysis ofI yielded an IC50 of 626.1 11.4 nM
and an nH of 1.0  0.2 (both n  6). However, in the same six
oocytes, F showed full amplitude over a broad range of picro-
toxin concentrations (Fig. 5F). This response profile is expected
for a classical open state blocker that plugs the pore without
FIGURE 5. Effects of GlyR inhibitors on current and fluorescence recordings fromMTSR-labeled 1R19C oocytes. A, current (upper panel) and fluores-
cence (lower panel) traces of MTSR-labeled 1R19C oocyte during consecutive, saturating [strychnine] (str), and [glycine] (gly) applications as indicated by
horizontal bars. B, current (upper panel) and fluorescence (lower panel) traces of MTSR-labeled 1R19C oocyte during co-application of EC50 [glycine] with
saturating [strychnine]. C, current and fluorescence dose-response relations for the inhibition by strychnine when co-applied with 1 mM glycine. D, current
(upper panel) and fluorescence (lower panel) traces of MTSR-labeled 1R19C oocyte during consecutive, saturating [picrotoxin] (PTX), and [glycine] (gly)
applications as indicated by horizontal bars. E, current (upper panel) and fluorescence (lower panel) traces of MTSR-labeled 1R19C oocyte during co-applica-
tion of EC50 [glycine] with saturating [picrotoxin]. F, current and fluorescence dose-response relations for the inhibition by picrotoxin when co-applied with 1
mM glycine. G, current (upper panel) and fluorescence (lower panel) traces of MTSR-labeled 1R19C oocyte during consecutive, saturating [ginkgolide C] (GC)
and [glycine] (gly) applications as indicated by horizontal bars. H, current (upper panel) and fluorescence (lower panel) traces of MTSR-labeled 1R19C oocyte
during co-application of EC50 [glycine] with saturating [ginkgolide C]. I, current and fluorescence dose-response relations for the inhibition by ginkgolide C
whenco-appliedwith 1mMglycine.Horizontal scale bars,20 s; vertical scale bars (upper panels), 2A; vertical scale bars (lower panels), 5%F. J, spectral emission
fromMTSR-labeled 1R19C oocytes before, after, and during the application of 1 mM glycine and 1 mM glycine 100 M ginkgolide C (average of five cells
each).K,differenceemission spectra fromMTSR-labeled1R19Coocytes recordedduringapplicationofglycine andglycineginkgolideC, respectively. Both
thegray trace (spectral emissionbefore applicationof agonist) and theblue tracearenormalized to the1mMglycineemissionpeak.Differenceemission spectra
were calculated as described in Fig. 2D.
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altering the normal open state conformation. Although it pro-
vides no evidence to support the previous conclusion for picro-
toxin imposing a distinct conformational change in the
M2–M3 loop (14), we cannot eliminate the possibility that such
a conformational change may occur
without a change in hydrophobicity
at R19C.
We next investigated the effects
of the GlyR pore blocker ginkgolide
C. As with strychnine and picro-
toxin, high concentrations (100 M)
of ginkgolideC applied alone did not
evoke detectable I or F (Fig. 5G).
When co-appliedwith 1mM glycine,
ginkgolide C decreased I but dra-
matically increased F (Fig. 5H).
Dose responses averaged from six
oocytes revealed an averagedI IC50
of 4.6  2.4 M and an nH of 0.5 
0.1 and an averaged F EC50 of
19.6 4.1M and an nH of 1.0 0.1
(Fig. 5I). Spectral analysis revealed
that the effect of ginkgolide C on the
MTSR emission spectrum was simi-
lar to that produced by saturating
glycine concentrations (compare
Fig. 5K with Fig. 2D, inset). An
exception is the ginkgolide C-in-
duced hump near 625 nm for which
we have no explanation. Overall, the
results indicate that pore block by
ginkgolide C induces a conforma-
tional change in M2–M3 similar to
that produced by saturating concen-
trations of glycine.
Analysis of the Effects of the GlyR
Potentiating Agent, Propofol—
Propofol is an intravenous anes-
thetic that potentiates GlyRs by
binding to the alcohol and anes-
thetic binding site located between
TM2 and TM3 (26, 27). Its potenti-
ation, particularly of taurine- and
-alanine-gated currents, is facili-
tated by mutations to R19 in 1
GlyRs (28). As propofol is hydro-
phobic and its putative binding site
lies in close proximity to the 19-la-
beled MTSR, it may directly affect
fluorescence by modulating the hy-
drophobicity of the environment
surrounding the fluorophore. How-
ever, therewas no significant change
in the basal fluorescence level when
MTSR-labeled 1R19CGlyRs were
incubated with 500 M propofol for
2 min. Similarly, preincubation with
propofol and subsequent MTSR
labeling in the presence of propofol (500 M each) did not
change Fmax or the resting fluorescence intensity (data not
shown). Following a 2-min incubation with 500 M propofol,
MTSR-labeled 1R19C GlyRs retained the ability to produce
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robust current and fluorescence changes in response to increas-
ing glycine concentrations (Fig. 6A). Propofol pretreatment sig-
nificantly increased the Imax but not the Fmax value and sig-
nificantly reduced themean glycine EC50 values for bothI and
F (Fig. 6B and Table 2).
The same propofol pretreatment drastically increased the
taurine- and -alanine-mediated I responses although their
F values were less affected (Fig. 6, C and D). The effects of
propofol on averaged I and F dose responses for taurine and
-alanine are summarized in Fig. 6, E and F, respectively, with
mean parameters of best fit to the dose-response curves sum-
marized in Table 2. As with glycine-mediated responses, the
taurine- and -alanine-mediated F EC50 values were shifted
to significantly lower values. The Fmax value for taurine was
significantly increased by propofol, whereas the corresponding
value for -alanine was not. The Imax values for both taurine
and -alanine were also significantly increased by propofol.
Considering that propofol converted-alanine and taurine into
highly efficacious agonists, we tested whether their F charac-
teristics may have changed tomore closely resemble those pro-
duced by glycine. Surprisingly, however, propofol had no effect
on the spectral maxima of the F increases induced by either
-alanine or taurine (Fig. 6, G and H).
DISCUSSION
Structural Basis for Fluorescence Change—Given the dis-
tance of R19C and L22C from the glycine-binding site (12)
and their position midway along the conformational wave that
extends from the binding site to the activation gate upon ago-
nist binding (11), we propose that fluorescence signals arising
from rhodamine-labeled R19CandL22Care not likely to sim-
ply reflect ligand binding. They are more likely to result from a
rotation or tilting of the M2 helix during the conformational
change that ultimately leads to channel opening. During this
global conformational rearrangement, the MTSR fluorophore
at the 19 position may move to a more hydrophobic environ-
ment. TMRM attached to L22Cmoves into a more hydropho-
bic environment when activated by glycine, but it moves into a
more hydrophilic environment when activated by taurine or
-alanine. However, we cannot rule out the possibility that a
quenching group moving toward or away from the fluoro-
phores may contribute to the observed fluorescence changes.
Our experiments do not allow us to discriminate among the
existing structural models of Cys loop receptor activation,
although they do permit us to compare M2 domain conforma-
tional changes produced by different ligands.
Agonist-induced Conformational Changes—Perhaps our
most dramatic result is that ivermectin activates the pore with-
out producing a significant F in the 19-attached MTSR.
Although it has been suggested previously that ivermectin and
glycine activate the GlyR pore via structurally different mecha-
nisms (21), the present result provides amuch stronger case for
this conclusion. The Cys loop receptor ivermectin-binding site
is yet to be identified. Being lipophilic, it is possible that iver-
mectin binds either to a transmembrane or an intracellular site.
Regardless ofwhere it binds or how it activates the receptor, it is
surprising that ivermectin opens the pore with no detectable
change in the conformation at the top of M2. This raises the
intriguing possibility that ivermectin produces conformational
changes at the internal part of theM2 domain only, perhaps via
an interaction with the M1–M2 linker.
Taurine and -alanine are low efficacy glycinergic agonists
that are converted into antagonists by R19 mutations (20, 23,
24). Although their efficacy at activatingGlyR currentswas very
weak, both ligands evoked large F responses that were not
accompanied by blue shifts in the spectral emission peak (Fig. 3,
F and G). This response profile differs drastically from that
produced by glycine, which was characterized by a close cou-
pling between I and F and a substantial blue shift in the
emission spectral peak. Thus, the conformational change at
R19 produced by these ligands is distinct from that produced
by glycine. This is not surprising because it was already evident
from their low efficacy that taurine and-alaninemust produce
FIGURE 6. Propofol effects on glycine-, taurine-, and -alanine-evoked currents in MTSR-labeled 1R19C oocytes. A, glycine-evoked current (upper
panel) and fluorescence (lower panel) recordings from MTSR-labeled 1R19C oocytes after a 2-min preincubation with 500 M propofol (Pro). B, glycine
dose-response relation for current and fluorescence inMTSR-labeled1R19Coocyteswith andwithout a 2-min preincubationwith 500Mpropofol. C andD,
current (upper panel) and fluorescence (lower panel) recordings fromMTSR-labeled1R19Coocytes during the application of 30mMglycine (black arrows), 50
mM taurine (blue arrows), and 50 mM -alanine (red arrows). D, black horizontal bars indicate application of 500 M propofol. E, taurine-evoked dose-response
relation for current and fluorescence in MTSR-labeled 1R19C oocytes with and without a 2-min. preincubation with 500 M propofol (Pro). F, -alanine-
evoked dose-response relation for current and fluorescence in MTSR-labeled 1R19C oocytes with and without a 2-min preincubation with 500M propofol
(Pro). Dashed lines indicate interrupted illumination to prevent photobleaching between applications. G and H, difference emission spectra from MTSR-
labeled 1R19C oocytes recorded during application of saturating [taurine] (G) and [-alanine] (H) before and after a 2-min preincubation with 500 M
propofol (Pro), respectively. Emission peaks after propofol treatment were normalized to those recorded before propofol treatment. Difference emission
spectra were calculated as described in Fig. 2D.
TABLE 2
Summary of results for glycine-, taurine-, and -alanine-evoked current and fluorescence recordings fromMTSR-labeled 1R19C oocytes
Results are shown for recordings before and after a 2-min preincubation with 500 M propofol (PRO). Displayed are values for half-maximal activation (EC50), number
of experiments (n) and maximal current and fluorescence responses (Imax and Fmax, respectively). All results for fluorescence are shown in boldface.
Agonist Construct EC50 I EC50 F n Imax Fmax n
M M A %
Glycine R19C 994 14 1070 46 7 8.3 0.6 21.4 1.9 19
R19CPRO 419 34 718 108 6 10.5 1.2 22.9 2.7 8
-Alanine R19C 2610 927 2030 344 6 0.19 0.03 13.2 1.7 7
R19CPRO 219 4 381 26 6 7.1 0.4 17.1 1.1 14
Taurine R19C NA 2350 443 8 0.04 0.01 7.6 0.7 8
R19CPRO 749 53 479 49 5 3.3 0.6 10.1 0.6 13
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different conformational changes to glycine. However, propo-
fol, which drastically increased the efficacy with which taurine-
and -alanine were able to activate I, had no effect on the
spectral properties of the concomitant F (Fig. 6, G and H).
This result is more significant as it shows that taurine and -al-
anine produce no F spectral change even when they strongly
activate the GlyR. This provides a stronger case for taurine and
-alanine activating the GlyR pore via a different conforma-
tional change to glycine. However, a weakness in this argument
is that theR19Cmutationmayhave altered structure and func-
tion to the extent that the results may not apply to the WT
GlyR.
For this reason, we compared the agonist-specific conforma-
tional changes experienced by a TMRM attached to the nearby
L22C residue. Again, we found that glycine produced a differ-
entF response to that elicited by taurine and-alanine (Fig. 4,
C and D). This shows that the agonist-specific conformational
changes do not pertain only to the functionally impaired
1R19C GlyRs but also to a nearby mutant with functional
characteristics that more closely resemble the WTGlyR.
Together, these results lead us to conclude that different ago-
nists activate the GlyR by producing different conformational
changes to the external region of theM2 domain. Thus, the top
of M2 seems to display a conformational mobility that is not
necessarily coupled to movements of the channel gate. Con-
versely, opening of the channel gate does not necessarily prop-
agate back to the top of M2.
Antagonists—Strychnine has long been considered a classical
competitive antagonist of the GlyR (1). Our finding that strych-
nine exhibits very similar inhibitory dose response profiles for
I and F is consistent with this notion. By displacing glycine
from its site, strychnine prevents glycine from binding and
hence from inducing its F change.
Picrotoxin is thought to bind in theGlyR pore and to produce
inhibition via an allosteric mechanism (25). We recently con-
cluded on the basis of a substituted cystine accessibility study
that it changes theM2–M3 loop conformation in amanner that
cannot be achieved by glycine (14). If so, then picrotoxin might
be expected to alter F in a way that cannot be achieved by
altering glycine concentration alone. However, we found that
Fproduced by picrotoxin plus glycine equals that produced by
glycine alone (Fig. 5,D–F). This response profile is expected for
a classical pore blocker that blocks current flow without alter-
ing the open state receptor conformation. However, we cannot
rule out the possibility that picrotoxin changes the conforma-
tion of the M2–M3 loop in a way that does not involve a F
change.
Several lines of evidence suggest that ginkgolides bind in the
GlyR pore (29–31), but there is no evidence to date that they
produce a conformational change upon binding. Ginkgolides
thus bind close to the covalently linked fluorophore. The results
of Fig. 5, G–K, demonstrate that ginkgolide C-induced inhibi-
tion is accompanied by both an increase inF and a blue shift in
the emission spectra maxima. Unexpectedly, ginkgolide C
affectsF at higher concentrations than those affectingI (Fig.
5I). This is difficult to reconcile with a model that assumes only
one ginkgolidemolecule binding per receptor.We propose that
the F changes are mediated by ginkgolide C binding to a dis-
crete, lower affinity site distinct from the well characterized
pore blocker site at the 6 level. In support of this, a molecular
docking study identified a putative ginkgolide-binding site near
the M2–M3 loop (31). An alternate explanation is that the rel-
atively large size of ginkgolides may force the pore to become
stabilized in the activated state. However, the observed discrep-
ancy between the F and I ginkgolide dose responses is not
readily explainable by this model.
Comparison with Previous VCF Studies—Chang and Weiss
(17) employed VCF to investigate molecular rearrangements at
three positions in and around the recombinant 1 -aminobu-
tyric acid type A receptor ligand binding pocket. They found
that two GABAergic (where GABA is -aminobutyric acid)
agonists produced a similar pattern ofF responses at the three
labeled positions. Competitive antagonists prevented these F
changes but also produced distinctF responses in the absence
of agonist. Perhaps most interestingly, picrotoxin produced a
large F at one of the labeled positions, providing strong evi-
dence that by binding in the pore it produces global conforma-
tional change (17). A more recent study on 12 and 122
-aminobutyric acid type A receptors showed that theFmag-
nitude monitored at two binding domain residues exhibited
subunit dependence (18). The results from these two studies
provide strong evidence for ligand- and subunit-specific con-
formational changes in the ligand binding domain. However,
they provide no information about whether these differential
movements translate into different movements at the pore.
Finally, Dahan et al. (15) investigated acetylcholine- and epi-
batidine-mediated F and I changes at muscle ()
nAChRs via a rhodamine label attached to the  subunit 19
position. They concluded that F reported a conformational
change at the subunit interface. TheF signal was alsomod-
ulated by the receptor desensitization status. Together with the
present study, these results indicate that the M2 conformation
reflects awide variety of influences, including the identity of the
bound agonist, the molecular identity of the labeled subunit,
and the desensitization status of the receptor.
Conclusion—VCFrecordings reveal that theGlyRagonists, gly-
cine, taurine, and ivermectin, produce different F changes at
fluorescently labeled 19 and 22 residues. The inhibitors, strych-
nine andpicrotoxin, producedF andI changes as expected for
a competitive antagonist and a channel blocker, respectively.
On the other hand, the putative channel blocker, ginkgolide C,
produced an increase in F that may have signaled a direct
interaction between MTSR and a low affinity ginkgolide site.
Taken together, our results suggest that the GlyR M2 domain
responds with distinct conformational changes to the binding
of different agonists.
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